Cagrilintide (2.5mg) / GLP-1 S (2.5mg)

Mechanism of Action: How the Blend Works

This dual peptide improves metabolism via:

Cagrilintide

• Slows gastric emptying for sustained fullness
• Decreases reward-driven and emotional eating behavior
• Stabilizes appetite signaling and feeding patterns

GLP-1 S

• Enhances insulin response only when glucose is present
• Decreases hunger signals in the hypothalamus
• Contributes to improved metabolic efficiency

Both pathways together deliver strong appetite-control synergy with improved tolerability.

Clinical Dosing Guide for Providers

For licensed medical professionals only.

Suggested Dosage

• Initiation Range: ~0.25mg weekly
• Therapeutic Range: 0.5–1mg weekly depending on response
• Program Duration: 12–30+ weeks depending on goals

Administration Notes

• Route: Subcutaneous injection
• Dosing frequency: Weekly, flexible timing (AM/PM, fed/fasted)

Reconstitution & Storage

• Reconstitute with bacteriostatic water
• Refrigerate after mixing
• Shelf life ~28 days after reconstitution

Common Clinical Stacks

• AOD-9604 — increased fat-breakdown signaling
• BPC-157 — GI support during rapid appetite reduction
• GH secretagogues — muscle retention and body-composition support

Ideal Candidate Profile

Potentially Good Candidates

• Early-stage metabolic therapy patients
• Individuals needing enhanced satiety without aggressive potency
• Those restarting weight-loss after a plateau
• Patients with impaired glucose tolerance or high A1C trends

Use With Caution

• History of pancreatitis
• Advanced gastrointestinal motility issues
• Patients using insulin — require monitoring

Potential Side Effects

Low-dose profile improves tolerability:

• Mild nausea or early satiety sensation
• Decreased appetite or slower digestion
• Rare: constipation or fatigue early in titration

Gradual dose escalation reduces likelihood and severity.

Frequently Asked Questions

1. What is this blend used for?
Appetite control, weight-loss support, and glucose stabilization.

2. Is this a good starter dose?
Yes — ideal for metabolic newcomers or tolerance testing.

3. How soon does it work?
Most patients notice appetite reduction within 3–7 days.

4. Does it help with cravings?
Yes — especially evening and stress-related eating.

5. Do patients need strict dieting?
Not required, but satiety improvements make better choices easier.

6. Is hypoglycemia a risk?
Low — insulin secretion is glucose-dependent.

7. Weekly dosing?
Yes — one injection per week.

8. Can it be combined with GLP-1 monotherapy?
This is a GLP-1 dual-pathway blend (amylin + GLP-1) — stronger together.

9. Who should avoid it?
Anyone with active pancreatitis risk until cleared by a clinician.

10. How is it stored?
Refrigerate after reconstitution.

Blend vs Similar Options

• Vs GLP-1 alone:
  Stronger satiety and craving control via amylin + GLP-1 synergy.
• Vs higher-dose blends:
  Better entry-level tolerability with fewer GI effects.
• Vs Tirzepatide:
  Different co-agonist system — GLP-1 + Amylin vs GLP-1 + GIP.

Research & Evidence Overview

Clinical data supports:

• Strong appetite-suppression outcomes
• Reduced binge-driven feeding habits
• Improved glucose control and A1C trends
• Sustained weight reduction with proper adherence

Expanding adoption in progressive obesity-medicine protocol design.

Product & Purity Assurance

99% purity

• Verified COA & endotoxin testing
• cGMP-certified manufacturing
• Provider-only dispensing

Legal & Medical Disclaimer

For licensed medical professionals only. Not intended to diagnose, treat, or cure any condition.